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Abstract: Unlike 5-hydroxytryptamine (5-HT, serotonin) 1 and 5-HT2, the effect of 5-HT3 receptors
on tumor cells is poorly understood. We conducted this study to determine whether the perioperative
use of 5-HT3 receptor antagonists, which are widely used antiemetics, impacts the recurrence and
mortality after lung cancer surgery and related anti-tumor mechanisms. From data on 411 patients,
propensity score matching was used to produce 60 1:2 matched pairs of patients, and variables
associated with the prognosis after open lung cancer surgery were analyzed. Additionally, the effects
of 5-HT3 receptor antagonists were confirmed in vitro on A549 human lung adenocarcinoma cells.
Cancer recurrence occurred in 10 (8.2%) and 14 (22.95%) patients (p = 0.005), treated or untreated, with
palonosetron or ramosetron. Perioperative usage of palonosetron or ramosetron was also associated
with lower recurrence rate after lung cancer surgery (hazard ratio (HR), 0.293; 95% confidence interval
(CI) 0.110–0.780, p = 0.0141). Our in vitro experiments also showed that palonosetron and ramosetron
inhibited cell proliferation and colony formation and reduced migration, which was associated with
autophagic cell death via the extracellular signal-regulated kinase (ERK) pathway. Palonosetron and
ramosetron may have anti-tumor potential against lung cancer cells, suggesting the need to consider
these drugs as first-choice antiemetics in patients undergoing lung cancer surgery.
Keywords: lung neoplasm; palonosetron; ramosetron; serotonin antagonist
1. Introduction
Even though surgical resection is the first-choice treatment of solid tumors, tumor cells not visible
to the eye can remain, seed, or migrate during surgery [1–4]. These remnant tumor cells can be
removed by a patient’s own immune system [5]; however, patients undergoing cancer surgery are often
older in age and immunocompromised [4,6,7]. Moreover, some anesthetics, as well as surgical stress,
were shown to further compromise patient immunity perioperatively. All of this can affect mortality
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and the long-term prognosis of the patient [8–11]. Accordingly, efforts to prevent perioperative
immunosuppression by mitigating increases in stress hormone and sympathetic activation and to
choose anesthetic agents and other drugs for minimizing recurrence after cancer surgery garnered
increasing interest in anesthesiology research.
Lung cancer is the leading cause of cancer deaths among men and women worldwide [12]. Even
after surgical resection, which can only be performed in fewer than 20% of patients diagnosed with
lung cancer, recurrence is frequent. In pathologic stage IA non-small-cell lung cancer, more than 10%
of patients experience recurrence after surgery [13]. The frequency of recurrence and poor survival in
lung cancer make it necessary to investigate remedial methods of lowering recurrence rates.
The antiemetic 5-hydroxytryptamine (5-HT, serotonin) 3 receptor antagonist (5-HT3RA) suppresses
the action of serotonin, which is a neurotransmitter that sends signals to the gastrointestinal tract
from the brain, resulting in vomiting [14]. Previous studies showed that serotonin acts as a mitogenic
factor in both normal and cancer cells and promotes the proliferation of various types of cancer
cells [15–17]. Most studies concerning the tumor mitogenic effects of serotonin focused on 5-HT1 and
5-HT2 receptors, but not 5-HT3 receptors [15,16,18,19].
We hypothesized that 5-HT3 receptors would also exhibit mitogenic potential and that
post-operative administration of its antagonist would improve oncologic outcomes after surgery.
In this study, we retrospectively investigated the effects of post-operative 5-HT3RA on recurrence and
mortality in patients that underwent open lung cancer surgery. Also, an in vitro study was performed
to identify the mechanism via which 5-HT3RA exerts its favorable effects on lung cancer cells.
2. Experimental Section
2.1. Retrospective Study
2.1.1. Study Population and Design
This retrospective study was approved by the Institutional Review Board (IRB) of Severance
Hospital, Yonsei University Health System, Seoul, South Korea (protocol number: 4–2018-0042;
date of approval: 11 March 2018). Because this was a retrospective study using electronic medical
records of anonymous patients who underwent lung cancer surgery, the IRB granted a waiver for
individual consent.
Data were collected from patients who underwent open lung cancer surgery between January
2009 and December 2014 in a tertiary hospital in Seoul, South Korea. Data from patients who received
anatomic resection, such as lobectomy and complete mediastinal lymph node dissection, were analyzed.
Demographic data, including age, sex, height, weight, and co-morbidities, such as hypertension,
diabetes mellitus, pulmonary diseases, were collected. In addition to cancer stage, pre-post-operative
chemotherapy or radiation therapy, type of anesthetic, common intraoperative drugs, intraoperative
colloid administration, and red blood cell transfusion were also analyzed as variables that could
potentially be associated with the prognosis of lung cancer after open surgery. Lung cancer stage was
measured according to the eighth edition of the American Joint Committee on Cancer staging system.
2.1.2. Statistical Analysis
The primary objective of this study was to compare recurrence and mortality rates in lung
cancer between perioperative palonosetron or ramosetron administration with and without 5-HT3RA.
The maximal follow-up period was set at 60 months. Demographic and perioperative characteristics
were analyzed using Student’s t-test for continuous variables and the chi-square test for categorical
variables. Potential factors affecting cancer recurrence and mortality after surgery were analyzed
using competing risk and the Cox proportional hazards model, and the risk of each variable was
calculated as a hazard ratio (HR) and 95% confidence interval (CI). Fine and Gray competing risk
analysis was performed for recurrence, with death as a competing risk. After screening for potentially
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significant variables in univariate analysis, multiple Cox regression analysis was performed including
factors in univariate analysis with p-values < 0.2. Overall survival rates during the study period
and the difference between survival curves according to palonosetron or ramosetron treatment were
examined using the Kaplan–Meier log-rank survival analysis method. Propensity score matching (PSM)
was applied to reduce selection bias, and confounders used for PSM included age, sex, and cancer
stage. Taking into account the original proportion of patient-to-group numbers and the total sample
size with statistical significance, 1:2 matching was conducted with propensity scores calculated with
logistic regression analysis with the aforementioned confounding factors. The risk of recurrence and
mortality with perioperative palonosetron or ramosetron administration with and without 5-HT3RA
was analyzed with conditional Cox proportional hazard regression. A p-value less than 0.05 was
considered as statistically significant. All statistical analyses were conducted with SAS version 9.4
(SAS Institute Inc., Cary, NC, USA) except for Kaplan–Meier curves, which were constructed using the
R package version 3.0.2 (www.r-project.org).
2.2. In Vitro Study
2.2.1. Cell Cultures and Drug Treatment
The A549 human lung adenocarcinoma cell line was purchased from American Type Culture
Collection (Manassas, VA, USA). The cells were cultured in Roswell Park Memorial Institute (RPMI)-1640
medium (Hyclone, Logan, Utah, USA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), l-glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin at 37 ◦C in a humidified
atmosphere of 5% CO2. Ondansetron, palonosetron, and ramosetron purchased from Sigma-Aldrich
were freshly dissolved in RPMI-1640 medium and applied to the A549 cells for 48 h. Bafilomycin A1
(Baf-1), a potent inhibitor of cellular autophagy, was purchased from Sigma-Aldrich.
2.2.2. Flow Cytometry
A549 cells were detached with 0.125% trypsin–ethylenediaminetetraacetic acid (EDTA) and fixed
in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min at 4 ◦C. The fixed cells were
then blocked in 10% FBS for 30 min on ice. Primary antibodies against 5-HT3A, 5-HT3B, 5-HT3C,
and 5-HT3D + E (Bioss, Massachusetts, USA) and secondary Alexa Fluor 555 immunoglobulin G
(Invitrogen) were added to the cell suspension and incubated at 4 ◦C in the dark for 1 h. The labeled
cells were resuspended in PBS containing 2% FBS after washing with incubation buffer and analyzed
using a BD FACScan flow cytometer (Becton Dickinson Biosciences).
2.2.3. Cell Viability
A549 cells were grown in 96-well plates to a density of 5 × 104 cells/mL before treatment with
ondansetron, palonosetron, or ramosetron for 24 or 48 h in complete media. Cells treated with solvent
only were used as a control. Cell viability was assessed using the EZ-Cytox Cell Viability Assay Kit
(DOGEN, Seoul, South Korea). Absorbance at 450 nm was measured for the experimental groups
using a plate reader. Experiments were performed in six biological replicates.
2.2.4. Cell Scraping Assay
A549 cells were seeded onto six-well plates at a density of 1 × 105 cells/mL and cultured in a
humidified atmosphere containing 5% CO2 at 37 ◦C. After 24 h, the cells reached 80–90% confluence as
a monolayer, which was gently scraped with a new 1-mL pipette tip across the center of each well.
The well was then washed gently with PBS three times to remove detached cells. Remaining cells were
grown in RPMI with 2% FBS containing ondansetron, palonosetron, or ramosetron for an additional
two days, after which images were captured using a light microscope (×10 magnification). Then,
the number of migrated cells was counted.
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2.2.5. Clonogenic Assay
A549 cells were seeded onto six-well plates at 5 × 104 cells/well and treated with ondansetron,
palonosetron, or ramosetron for two days. Next, 200 cells were plated per well into six-well plates
and incubated for an additional 10 days. Images of colonies were captured using a light microscope
(×10 magnification), and colony size was measured using Image J software (NIH, Bethesda, MD, USA).
2.2.6. Western Blot Analysis
A549 cells were treated with ondansetron, palonosetron, or ramosetron for 48 h, washed twice
with cold PBS, and lysed in radio-immunoprecipitation assay buffer containing protease inhibitors
(10µg/mL each of aprotinin, bestatin, l-leucine, and pepstatin A) dissolved in a solution of 150 mM NaCl,
10 mM Tris, 1 mM EDTA, 1 mM benzenesulfonyl fluoride, and 1% NP-40. Total protein concentration
was determined by Quick Start Bradford reagent (Bio-Rad, Hercules, CA, USA). Whole-cell extracts
(50 µg) were separated on 10–15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels and
transferred onto Immobilon P-transfer membranes (Millipore, Billerica, MA, USA). The membranes
were incubated successively with primary and secondary antibodies. Antibody binding was detected
using Amersham ECL Select Western blotting detection reagent (GE Healthcare, Buckinghamshire,
UK). Primary antibodies included light chain 3B (LC3B, 1:1000, Novus Biologicals, Centennial, CO,
USA), total extracellular signal-regulated kinase (ERK, 1:1000, Cell Signaling Technologies, Danvers,
MA, USA), phospho-ERK (1:1000, Cell Signaling Technologies), autophagy-related 16 like 1 (ATG16L1,
1:1000, Cell Signaling Technologies), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:2000,
Cell Signaling Technologies).
2.2.7. Autophagic Flux Assay
A549 cells were cultured with or without ondansetron, palonosetron, or ramosetron for 24 h.
To confirm the autophagic flux, A549 cells were added to Baf-1 (50 nM) 2 h before the harvest for
Western blot analysis, washed twice with cold PBS, and lysed in radio-immunoprecipitation assay buffer
containing protease inhibitors. Western blot analysis was performed for LC3B and GAPDH antibodies.
2.2.8. Statistical Analysis
All data from the in vitro experiments are expressed as means (standard deviation) and were
compared using one-way analyses of variance with Bonferroni post hoc multiple comparisons.
A p-value <0.05 was considered statistically significant.
3. Results
3.1. Study Population, Demographic Data, and Perioperative Characteristics
A total of 446 cases of open surgery for lung cancer were reviewed. We excluded 33 cases who
died within 30 days after surgery and seven cases diagnosed with stage IV cancer. The data of the
remaining 406 patients were examined in this study. During the perioperative period, 308 patients
(P-R group) were treated with palonosetron or ramosetron. Meanwhile, 98 patients (No P-R group)
did not use these drugs by any method; they received other medications for post-operative nausea
and vomiting, such as metoclopramide, ondansetron, or dexamethasone. All patients underwent
general anesthesia using volatile anesthetic and remifentanil infusion. For post-operative pain control,
epidural patient-controlled analgesia was performed.
Appropriate PSM produced 60 1:2 matched pairs with exclusion of 226 cases (188 cases with
palonosetron or ramosetron and 38 cases without palonosetron or ramosetron). Demographic characteristics
are listed in Table 1. When comparing demographic data between the two groups after PSM, differences
were observed in recurrence and mortality after surgery.
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Table 1. Demographic and perioperative characteristics.
Total Population Propensity-Matched Population
P-R Group
(n = 308)
No P-R
Group
(n = 98)
p-Value P-R Group(n = 120)
No P-R
Group
(n = 60)
p-Value
Age 68.7 ± 9.7 67.0 ± 10.7 0.144 67.9 ± 9.8 68.4 ± 9.7 0.718
Sex (M/F) 239/69 77/21 0.840 85/35 44/16 0.810
BMI 23.60 ± 2.84 22.93 ± 3.82 0.113 23.73 ± 3.05 23.18 ± 2.99 0.2535
Comorbidity
HTN 92 (29.87) 35 (35.71) 0.286 34 (28.33) 21 (35) 0.427
DM 43 (13.96) 12 (12.24) 0.666 18 (15) 7 (11.67) 0.377
Cancer stage <0.0001 0.855
I 228 (74.03) 49 (50) 93 (77.50) 46 (76.67)
II 39 (12.66) 31 (31.63) 19 (15.83) 10 (16.67)
III 38 (12.34) 18 (18.36) 8 (6.67) 4 (6.67)
Pathology 0.1278 0.801
Squamous cell
carcinoma 67 (21.75) 30 (30.61) 31 (25.83) 14 (23.34)
Adenocarcinoma 222 (72.08) 65 (66.33) 84 (70) 44 (73.34)
Others 19 (6.17) 3 (3.06) 5 (4.17) 2 (3.34)
Pre-operative CTx 19 (6.17) 9 (9.18) 0.305 9 (7.50) 4 (6.67) >0.9999
Operative (op) time 179.5 ± 73.3 183.1 ± 77.8 0.702 172.3 ± 71.1 185.3 ± 76.2 0.313
Post-op CTx 65 (21.10) 30 (30.61) 0.053 19 (15.83) 18 (30) 0.077
Post-op RTx 5 (1.62) 2 (2.04) 0.782 2 (1.67) 1 (1.67) >0.9999
Recurrence 76 (24.68) 44 (44.90) <0.0001 26 (21.67) 22 (36.67) 0.005
Mortality 64 (20.78) 35 (35.71) 0.003 17 (14.17) 14 (23.34) 0.004
P-R group patients were treated with ramosetron or palonosetron perioperatively. No P-R group patients were treated
without ramosetron and palonosetron perioperatively. HTN, hypertension; DM, diabetes mellitus; CTx, chemotherapy; RTx,
radiotherapy; M, male; F, female; BMI, body mass index.
3.2. Association between the Use of Palonosetron or Ramosetron, Cancer Recurrence, and Mortality after Surgery
The mean follow-up time in all patients was 40.3 ± 16.1 months. During this time period, cancer
recurrence occurred in 72 patients in the unmatched study population. Among the 180 matched
individuals, cancer recurrence occurred in 26 (21.67%) patients in the P-R group and 22 (36.67%)
patients in the No P-R group (p = 0.005). All-cause mortality occurred in 68 patients in the unmatched
study population. For the matched population, all-cause mortality occurred in 17 (14.17%) patients in
the P-R group and 14 (23.34%) patients in the No P-R group (p = 0.004). Kaplan–Meier curves for cancer
recurrence and overall mortality of patients treated with and without palonosetron or ramosetron
are shown in Figure 1. The log-rank test of recurrence and mortality revealed significant differences
between the P-R and No P-R groups (p = 0.04 and p = 0.116, respectively).
J. Clin. Med. 2019, 8, 1380 6 of 16 
 
palonosetron or ramosetron are shown in Figure 1. The log-rank test of recurrence and mortality 
revealed significant differences between the P-R and No P-R groups (p = 0.04 and p = 0.116, 
respectively). 
 
Figure 1. Kaplan–Meier curves for cancer recurrence and overall survival of patients treated with 
and without palonosetron or ramosetron. P-R group patients were treated with ramosetron or 
palonosetron perioperatively. No P-R group patients were treated without ramosetron and 
palonosetron perioperatively. 
Table 2 shows findings from the Cox regression analysis of factors associated with increasing 
recurrence rate. According to multivariate Cox regression analysis with 1:2 PSM, the only factor 
associated with lower recurrence rate was perioperative usage of palonosetron or ramosetron (HR, 
0.547; 95% CI 0.308–0.974, p = 0.0404). A higher cancer stage (Stage II and III as opposed to Stage I) 
was found to be associated with a greater risk of recurrence. 
Table 2. Univariate and multivariate regression analysis of variables after propensity score 
matching with recurrence after open lung surgery for lung cancer. 
Recurrence 
Univariate Analysis Multivariate Analysis 
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value 
5-HT3RA usage     
No P-R group 1  1  
P-R group 0.584 (0.331–1.03) 0.0634 0.547 (0.308–0.974) 0.0404 
Age 0.987 (0.959–1.015) 0.3682 0.981 (0.954–1.009) 0.1823 
Sex     
Male 1    
Female 1.285 (0.705–2.342) 0.4127 1.488 (0.793–2.792) 0.2161 
BMI 1.000 (0.91–1.099) >0.9999   
Cancer stage     
I 1  1  
II 2.534 (1.312–4.895) 0.0056 2.641 (1.357–5.137) 0.0042 
III 3.836 (1.671–8.805) 0.0015 4.451 (1.887–10.498) 0.0006 
Pre-operative HTN     
No 1    
Yes 0.721 (0.374–1.389) 0.3279   
Pre-operative DM     
Figure 1. Kaplan–Meier curves for cancer recurrence and overall survival of patients treated with and
w thout palonosetron or ramos tron. P-R g oup patients were tr ated with r mosetron or palonosetron
perioperatively. N P-R g up patients we e treated without ramosetron and palonosetron perioperatively.
J. Clin. Med. 2019, 8, 1380 6 of 15
Table 2 shows findings from the Cox regression analysis of factors associated with increasing
recurrence rate. According to multivariate Cox regression analysis with 1:2 PSM, the only factor
associated with lower recurrence rate was perioperative usage of palonosetron or ramosetron (HR, 0.547;
95% CI 0.308–0.974, p = 0.0404). A higher cancer stage (Stage II and III as opposed to Stage I) was
found to be associated with a greater risk of recurrence.
Table 2. Univariate and multivariate regression analysis of variables after propensity score matching
with recurrence after open lung surgery for lung cancer.
Recurrence
Univariate Analysis Multivariate Analysis
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
5-HT3RA usage
No P-R group 1 1
P-R group 0.584 (0.331–1.03) 0.0634 0.547 (0.308–0.974) 0.0404
Age 0.987 (0.959–1.015) 0.3682 0.981 (0.954–1.009) 0.1823
Sex
Male 1
Female 1.285 (0.705–2.342) 0.4127 1.488 (0.793–2.792) 0.2161
BMI 1.000 (0.91–1.099) >0.9999
Cancer stage
I 1 1
II 2.534 (1.312–4.895) 0.0056 2.641 (1.357–5.137) 0.0042
III 3.836 (1.671–8.805) 0.0015 4.451 (1.887–10.498) 0.0006
Pre-operative HTN
No 1
Yes 0.721 (0.374–1.389) 0.3279
Pre-operative DM
No 1
Yes 1.057 (0.474–2.357) 0.8918
Pre-operative CTx
No 1
Yes 0.78 (0.242–2.513) 0.6777
Operative time 0.996 (0.992–1.001) 0.0823
Post-operative CTx
No 1
Yes 0.779 (0.377–1.61) 0.5001
Post-operative RTx
No 1
Yes 0 0.9841
Pathology
Squamous cell carcinoma 1
Adenocarcinoma 1.272 (0.613–2.636) 0.5182
Others 1.626 (0.351–7.525) 0.5342
P-R group patients were treated with ramosetron or palonosetron perioperatively. No P-R group patients were treated without
ramosetron and palonosetron perioperatively. 5-HT3RA, 5-hydroxytryptamine 3 receptor antagonist; HTN, hypertension; DM,
diabetes mellitus; CTx, chemotherapy; RTx, radiotherapy; BMI, body mass index; CI, confidential interval.
Table 3 shows the results of Cox regression analysis for factors associated with increasing overall
survival during the follow-up period. According to the multivariate Cox regression analysis with
1:2 PSM, perioperative usage of palonosetron or ramosetron was not associated with lower mortality
rate. A higher cancer stage (Stage III as opposed to Stage I) was found to be associated with greater
risk of mortality (HR, 5.872; 95% CI 2.179–15.82, p = 0.0005).
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Table 3. Univariate and multivariate regression analysis of variables after propensity score matching
with expire rate after open lung surgery for lung cancer.
Expire
Univariate Analysis Multivariate Analysis
Hazard Ratio
(95% CI) p-Value
Hazard Ratio
(95% CI) p-Value
5-HT3RA usage
No P-R group 1 1
P-R group 0.611 (00.301–1.241) 0.1729 0.553 (0.264–1.158) 0.1164
Cancer stage
I 1 1
II 2.421 (1.045–5.612) 0.0392 2.085 (0.846–5.139) 0.1106
III 4.5 (1.771–11.436) 0.0016 5.872 (2.179–15.82) 0.0005
Sex
Male 1
Female 1.391 (0.666–2.903) 0.3794 1.854 (0.842–4.081) 0.125
Age 0.986 (0.951–1.022) 0.4381 0.974 (0.941–1.009) 0.1402
BMI 1.008 (0.897–1.133) 0.8931
Pre-operative HTN
No 1
Yes 0.398 (0.153–1.037) 0.0594
Pre-operative DM
No 1
Yes 0.628 (0.191–2.065) 0.4434
Operative time 0.996 (0.99–1.001) 0.0986
Pre-op CTx
No 1
Yes 0.373 (0.051–2.733) 0.3317
Post-op CTx
No 1
Yes 0.517 (0.181–1.478) 0.2184
Post-op RTx
No 1
Yes 0 0.988
Pathology
Small cell carcinoma 1 1
Adenocarcinoma 0.466 (0.218–0.995) 0.0486 0.520 (0.230–1.175) 0.1159
Others 2.097 (0.584–7.521) 0.256 3.565 (0.866–14.681) 0.0784
P-R group patients were treated with ramosetron or palonosetron perioperatively. No P-R group patients were treated without
ramosetron and palonosetron perioperatively. 5-HT3RA, 5-hydroxytryptamine 3 receptor antagonist; HTN, hypertension; DM,
diabetes mellitus; CTx, chemotherapy; RTx, radiotherapy; BMI, body mass index; CI, confidential interval.
3.3. 5-HT3 Receptor Confirmation in A549 Cell
Flow cytometry experiments were performed to identify 5-HT3 receptor subtypes present in A549
cells. The expression levels of 5-HT3A, 5-HT3B, 5-HT3C, and 5-HT3D + E were 11.6%, 87.5%, 86%, and
87.6%, respectively (results are provided in Appendix A Figure A1).
3.4. 5-HT3RAs Inhibit A549 Cell Proliferation in a Dose-Dependent Manner
To determine the effects of 5-HT3RAs on A549 cells, we performed a cell viability assay using
cultures exposed to 5-HT3RAs at varying doses from 0.1 to 40 µg/mL for ondansetron, 0.025 to 8 µg/mL
for palonosetron, and 0.01 to 4 µg/mL for ramosetron. In the case of ondansetron, only concentrations
greater than 5 µg/mL showed differences in cell viability after the first day, compared to control cells.
However, palonosetron (≥0.05 µg/mL) and ramosetron (≥0.1 µg/mL) caused the cells to lose their
proliferative capabilities (p < 0.05). After the second day, all of the 5-HT3RAs significantly inhibited
cell proliferation, compared to control cells, with ondansetron (≥5 µg/mL), palonosetron (≥0.05 µg/mL),
and ramosetron (≥0.05 µg/mL) exhibiting the most potent effect (p < 0.05) (Figure 2A).
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3.5. 5-HT3RAs Inhibit Cell Migration and Colony Formation in A549 Cells
We examined the effect of 5-HT3RAs on cell migration and colony formation in A549 cells.
Palonosetron (8 µg/mL) and ramosetron (4 µg/mL), but not ondansetron (40 µg/mL), inhibited
cell migration, compared to the control (p < 0.05) (Figure 2B). The clonogenic assay revealed that
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ondansetron, palonosetron, and ramosetron treatment all led to a decrease in colony size, compared to
the control (p < 0.05). However, the sizes of colonies treated with palonosetron and ramosetron were
smaller than those treated with ondansetron (Figure 2C).
3.6. 5-HT3RAs Induce Autophagy via the ERK Signaling Pathway
When compared with the control cells, the level of LC3 protein was increased in the
5-HT3RA-treated cells, which was accompanied by ERK activation (Figure 3A). When an ERK
inhibitor (U0126, 10 mM) was added to the 5-HT3RA-treated cells, LC3 protein levels were reversed
(Figure 3B), suggesting that 5-HT3RAs induce autophagy via the ERK pathway in A549 cells. We also
investigated whether 5-HT3RAs affect the expression of p62 and ATG proteins, such as ATG3, ATG5,
ATG7, and ATG12, which are known to be associated with apoptotic cell death; however, 5-HT3RAs
did not change their expression levels, compared to control, in A549 cells (data not shown).
J. Clin. Med. 2019, 8, 1380 10 of 16 
 
to the control (p < 0.05). However, the sizes of colonies treated with palonosetron and ramosetron 
were smaller than those treated with ondansetron (Figure 2C). 
3.6. 5-HT3RAs Induce Autophagy via the ERK Signaling Pathway 
When compared with the control cells, the level of LC3 protein was increased in the 
5-HT3RA-treated cells, which was accompanied by ERK activation (Figure 3A). When an ERK 
inhibitor (U0126, 10 mM) was added to the 5-HT3RA-treated cells, LC3 protein levels were reversed 
(Figure 3B), suggesting that 5-HT3RAs induce autophagy via the ERK pathway in A549 cells. We 
also investigated whether 5-HT3RAs affect the expression of p62 and ATG proteins, such as ATG3, 
ATG5, ATG7, and ATG12, which are known to be associated with apoptotic cell death; however, 
5-HT3RAs did not change their expression levels, compared to control, in A549 cells (data not 
shown). 
 
Figure 3. 5-HT3 receptor antagonists induce autophagy via extracellular signal-related kinase (ERK) 
activation in lung cancer cells. (A) Levels of phospho-ERK, total-ERK, light chain 3B (LC3B), and 
autophagy-related 16 like 1 (ATG16L1) were determined by Western blotting. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control. (B) A549 cells 
were treated with or without ERK inhibitor (U0126, 10 mM) before a 1-h treatment with 5-HT3 
receptor antagonist. Levels of phospho-ERK, total-ERK, and LC3B were determined by Western 
blotting. GAPDH served as a loading control; * p < 0.05. 
3.7. 5-HT3RAs Act as Autophagy Inducers in A549 Cells 
The level of LC3 protein was increased in the 5-HT3RA-treated cells compared to the control 
cells. When Baf-1 was added to the 5-HT3RA-treated cells, the LC3 protein levels were significantly 
increased compared to the 5-HT3RA-treated cells without the addition of Baf-1 (Figure 4). 
Figure 3. 5-HT3 receptor antagonists induce autophagy via extracellular signal-related kinase (ERK)
activation in lung cancer cells. (A) Levels of phospho-ERK, total-ERK, light chain 3B (LC3B), and
autophagy-related 16 like 1 (ATG16L1) were determined by Western blotting. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) served as a loading control. (B) A549 cells were treated with or without ERK
inhibitor (U0126, 10 mM) before a 1-h treatment with 5-HT3 receptor antagonist. Levels of phospho-ERK,
total-ERK, and LC3B were determined by Western blotting. GAPDH served as a loading control; * p < 0.05.
3.7. 5-HT3RAs Act as Autophagy Inducers in A549 Cells
The level of LC3 protein was increased in the 5-HT3RA-treated cells compared to the control
cells. When Baf-1 was added to the 5-HT3RA-treated cells, the LC3 protein levels were significantly
increased compared to the 5-HT3RA-treated cells without the addition of Baf-1 (Figure 4).
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Figure 4. 5-HT3 receptor antagonists function as novel autophagy inducers in lung cancer cells. A549
cells were treated with or without ondansetron (40 µg/mL), palonosetron (8 µg/mL), or ramosetron
(4 µg/mL) for 24 h and then added to 50 nM bafilomycin A1 (Baf-1) 2 h before observation. The level of
LC3B was determined by Western blotting. GAPDH served as a loading control; * p < 0.05 vs. untreated
cells, # p < 0.05 vs. 5-HT3RA-treated cells.
4. Discussion
5-HT3RAs are widely used for the prevention of post-operative or chemotherapy-induced nausea
and vomiting. To the best of our knowledge, this is the first study to investigate the anti-tumor
potential of 5-HT3RAs. The findings of the present retrospective analysis suggest the possibility
that post-operative administration of palonosetron and ramosetron could lower tumor recurrence
after surgery in patients undergoing open thoracotomy for lung cancer. The results of our in vitro
experiments also demonstrated that palonosetron and ramosetron inhibit cell proliferation, migration,
and colony formation, and that high doses of ondansetron inhibit cell proliferation and migration of
A549 cells, which appeared to be associated with autophagic cell death linked to ERK activation.
Serotonin is a well-known monoamine neurotransmitter that is biochemically derived from
tryptophan. This small molecule is known to exist mainly in the gastrointestinal tract, blood platelets,
and the central nervous system in humans and animals, acting as a gastrointestinal motility controller,
growth factor, and anti-depressant. Serotonin is also known to act as a mitogenic factor in normal cells
and in cancer cells [15–17]. This neurotransmitter acts on various types of 5-HT receptors that comprise
a large, complex family of receptors, and promotes the proliferation of various types of cancer cells,
including prostate, lung, and colon cancer cells. There are seven known families of 5-HT receptors and
13 receptor subtypes in humans [20]. In particular, 5-HT1 and 5-HT2 receptors were reported to be
closely related to the aggressive tendency of cancer cells [15,16,18,19]. Based on these reports, several
studies attempted to examine whether antagonism of 5-HT1 and 5-HT2 receptors can prevent cancer
cell growth. Unlike the other G-protein-coupled 5-HT receptors, 5-HT3 receptors are involved in
pumping sodium and potassium ions during neuron activation [20]. However, it is not known which
5-HT3 receptor subtypes are present in lung cancer cells. From the results of flow cytometry, we found
that 5-HT3B, 3C, and 3D + E were present in A549 cells; 5-HT3A was present in small amounts.
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In our retrospective analysis, the perioperative use of palonosetron or ramosetron in lung cancer
patients was found to decrease post-operative lung cancer recurrence rate. This suggests that 5-HT3
receptors, such as the previously studied 5-HT1 and 5-HT2 receptors, might have the potential to affect
tumor mitogenesis. These results are meaningful and indicate that further investigation into the use of
5-HT3RAs as antiemetics in clinical practice is important.
Interestingly, our data indicated that ondansetron does not reduce tumor recurrence or overall
mortality after lung cancer surgery. Ondansetron was the first 5-HT3RA developed and possesses a
relatively short half-life, compared to other 5-HT3RAs. Ramosetron exhibits a significantly greater
binding affinity for 5-HT3 receptors and a slower dissociation rate from receptor binding, resulting
in more potent and longer effects (up to 48 h) than ondansetron [21]. Palonosetron is the first of
the “second-generation” 5-HT3RAs and has superior effects due to higher receptor binding affinity,
compared to first-generation drugs. The mean elimination half-life of palonosetron is about 40 h [22].
Our results demonstrated that palonosetron and ramosetron produce a positive effect on lung cancer
recurrence-free survival, whereas ondansetron does not. These effects appear to be related to the
potency of 5-HT3RA. Several clinical trials comparing the antiemetic efficacy of 5-HT3RAs also showed
that palonosetron and ramosetron are superior to ondansetron [23,24].
Our cell viability experiments were performed with references to serum concentrations of the drugs
used in clinical situations, as described in previous studies [25–27]. Thus, ondansetron, palonosetron,
and ramosetron were tested with 0.1, 0.025, and 0.01 µg/mL minimum concentrations, respectively.
The results demonstrated that all three agents inhibited A549 proliferation, although this differed
by concentration. After two days of treatment, significant inhibition of A549 cell proliferation was
found for palonosetron at two times the actual clinical blood concentration and for ramosetron at five
times the actual clinical blood concentration. Meanwhile, ondansetron treatment only inhibited A549
proliferation at concentrations of 50 times or more the clinical blood concentration. These data are
consistent with our retrospective results that showed that ondansetron did not decrease recurrence rate
or mortality after open thoracotomy for lung cancer. However, a well-controlled prospective study
is needed that takes into consideration that these 5-HT3RAs have different durations and frequency
of administration.
The role of serotonin on tumor growth is thought to be concentration-dependent [28]. High doses
of serotonin exhibit a growth stimulatory effect in aggressive cancers and carcinoids. Results from our
in vitro study showed that 5-HT3RAs inhibit proliferation of lung cancer cells in a dose-dependent
manner. However, at lower concentrations, palonosetron and ramosetron exhibited greater ability to
inhibit lung cancer cell proliferation than ondansetron. Subsequent studies on the ability of 5-HT3RAs
to inhibit cancer cells at any dose in vivo are important due to the variation in clinical doses used and
binding capacities observed.
The malignant potential of tumor cells is reflected by their increased proliferation, migration, and
colony formation abilities. Because these mechanisms directly lead to tumor recurrence, previous
studies focused on finding mechanisms of regulation of different types of cancer [29,30]. Our results
showed that 5-HT3RAs could impair A549 cell colony formation and that palonosetron and ramosetron
could reduce A549 cell migration. Although it was not statistically sufficient, a trend of reduction
in migration was also observed in the ondansetron-treated A549 cells. These results suggest that
5-HT3RAs could possess anti-tumor potential in lung cancer cells.
Autophagic cell death, which is another type of programmed cell death, is the process via which
the cell degrades its own organelles and some proteins through the formation of autophagosomes, with
the nucleus remaining intact until the late stage of cell death [31]. This cellular process is known to play
an important role in health and the pathogenesis of many diseases, including cancers [32,33]. Many
publications concluded that autophagy stimulates cell death in mammalian cells and non-mammalian
systems [34]. Also, ERK signaling was shown to be associated with autophagy by interacting with
LC3 [35–37]. Our in vitro data show that the expression of autophagic markers, such as LC3, was
increased in association with ERK activation (Figure 3A,B).
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To confirm the autophagic effect of 5-HT3RAs, we performed an additional experiment using Baf-1.
During autophagic cell death, autophagosomes then fuse with lysosomes facilitating the degradation of
engulfed cargo by lysosomal proteases. Baf-1, an inhibitor of autophagosome–lysosome fusion, acts by
inhibiting the late phase of autophagy [38]. LC3 levels were increased in Baf-1-treated cells compared to
the 5-HT3RA-treated cells (Figure 4), demonstrating that 5-HT3RAs act as strong autophagy inducers
and the growth inhibitory effects of 5-HT3RAs are associated with autophagy via ERK activation in
lung cancer cells.
A previous study in hepatocellular carcinoma showed that inhibition of autophagy is induced via
a 5-HT2 receptor related pathway [39]. Research on prostate cancer cells showed that 5-HT1A/B can
induce significant growth inhibition and apoptosis [40]. The 5-HT3 receptor acts through mechanisms
that are different from other receptors [20], suggesting that the 5-HT3 receptor may function via a
unique mechanism for promoting cancer cell survival or growth. Several studies concluded that 5-HT is
involved in promoting cell survival and the growth of various cancer cells by activating cancer-specific
5-HT receptors. Thus, although the mechanism is different, this study suggests that 5-HT3RAs can
be considered as candidates for cancer therapy. Further research is needed to explore the precise
molecular mechanisms underlying this process.
There are potential limitations of this study. Firstly, the main limitation of this study is its
retrospective design. Uncontrolled and unrecognized biases are frequent in such studies. Nevertheless,
our data can be considered reliable because all patients were managed perioperatively in a similar
manner at the same hospital over a study period. Furthermore, anesthetic management was relatively
consistent. Secondly, despite planning to study the effects of 5-HT3 on lung cancer, ondansetron,
which is a kind of 5-HT3RA, was included in the No P-R group as a control. As mentioned above,
the authors considered this to be a problem related to the potency of ondansetron. This limitation
of the retrospective study involving low-potency ondansetron should be supplemented with further
prospective randomized studies. Thirdly, the patient number in the P-R group was much higher than
that in the No P-R group, due to the advantages of drug efficacy and duration. We tried to supplement
this limitation with PSM, and we also performed 1:2 matching to obtain sufficient numbers of patients
for statistically significant analysis.
Overall, more in vivo research and clinical studies are needed to understand how the mechanisms
identified in our in vitro research work together and to determine the actual clinical doses of 5-HTRAs
required to have a significant impact on recurrence and survival in patients undergoing surgery for
lung cancer.
5. Conclusions
The present study showed the possibility that perioperative administration of palonosetron or
ramosetron has anti-tumor potential associated with increased recurrence-free survival in patients after
open thoracotomy for lung cancer. Our in vitro experiments also showed that 5-HT3RAs suppress the
growth of cancer cells via activation of ERK and autophagy. Once additional molecular and prospective
clinical studies are conducted to confirm the effects of 5-HT3RA on tumor cells, the anti-tumor potential
of palonosetron and ramosetron might be considered when selecting antiemetics in cancer patients,
especially during the post-operative period.
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